DMPK perspective on quantitative model analysis for chimeric antigen receptor cell therapy: Advances and challenges DOI Creative Commons
Akihiko Goto, Yuu Moriya, Miyu Nakayama

et al.

Drug Metabolism and Pharmacokinetics, Journal Year: 2024, Volume and Issue: 56, P. 101003 - 101003

Published: Feb. 14, 2024

Chimeric antigen receptor (CAR) cells are genetically engineered immune that specifically target tumor-associated antigens and have revolutionized cancer treatment, particularly in hematological malignancies, with ongoing investigations into their potential applications solid tumors. This review provides a comprehensive overview of the current status challenges drug metabolism pharmacokinetics (DMPK) for CAR cell therapy, emphasizing on quantitative modeling simulation (M&S). Furthermore, recent advances model analysis been reviewed, ranging from clinical data characterization to mechanism-based connects vitro vivo nonclinical study data. Additionally, future perspectives areas improvement therapy translation reviewed. includes using formulation quality considerations, appropriate animal models, refinement models bottom-up approaches, enhancement bioanalytical methodology. Addressing these within DMPK framework is pivotal facilitating ultimately enhancing patients' lives through efficient therapies.

Language: Английский

DMPK perspective on quantitative model analysis for chimeric antigen receptor cell therapy: Advances and challenges DOI Creative Commons
Akihiko Goto, Yuu Moriya, Miyu Nakayama

et al.

Drug Metabolism and Pharmacokinetics, Journal Year: 2024, Volume and Issue: 56, P. 101003 - 101003

Published: Feb. 14, 2024

Chimeric antigen receptor (CAR) cells are genetically engineered immune that specifically target tumor-associated antigens and have revolutionized cancer treatment, particularly in hematological malignancies, with ongoing investigations into their potential applications solid tumors. This review provides a comprehensive overview of the current status challenges drug metabolism pharmacokinetics (DMPK) for CAR cell therapy, emphasizing on quantitative modeling simulation (M&S). Furthermore, recent advances model analysis been reviewed, ranging from clinical data characterization to mechanism-based connects vitro vivo nonclinical study data. Additionally, future perspectives areas improvement therapy translation reviewed. includes using formulation quality considerations, appropriate animal models, refinement models bottom-up approaches, enhancement bioanalytical methodology. Addressing these within DMPK framework is pivotal facilitating ultimately enhancing patients' lives through efficient therapies.

Language: Английский

Citations

1